Research of oral prodrugs: Opportunities and challenges

Yaoxue Xuebao

Volumn 43, Issue 4, 2008, Pages 343-349

  Cao, Feng ^a   Ping, Qi Neng ^a   Chen, Jun ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

Author keywords

Oral absorption; Peptide transporter; Targeted prodrug

Indexed keywords

PRODRUG;

ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; REVIEW; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INTESTINAL ABSORPTION; PRODRUGS; SOLUBILITY;

EID: 44649115150     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Gomez-Orellana I. Strategies to improve oral drug bioavailability [J]. Expert Opin Drug Deliv, 2005, 2:419-433.
2. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs [J]. Expert Opin Drug Deliv, 2007, 4:403-416.
3. Ettmayer P, Amidon GL, Clement B, et al. Lessoms learned from marketed and investigational prodrugs [J]. J Med Chem, 2004, 47:2393-2404.
4. Beaumont K, Webster R, Gardner I, et al. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist [J]. Curr Drug Metab, 2003, 4:461-485.
5. Djaldetti R, Inzelberg R, Giladi N, et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease [J]. Mov Disord, 2002, 17:297-302.
6. Brouwers J, Tack J, Augustijns P. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation [J]. Int J Pharm, 2007, 336:302-309.
7. Cho H, Chung Y. Water soluble cyclosporine mono-methoxy poly (ethyleneglycol) conjugates as potential prodrugs [J]. Arch Pharm Res, 2004, 27:662-669.
8. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility [J]. Adv Drug Deliv Rev, 2007, 59:677-694.
9. Abrams WB, Davies RO, Gomez HJ. Clinical pharmacology of enalapril [J]. J Hypertens Suppl, 1984, 2:S31-36.
10. Williams PE, Brown AN, Rajaguru S, et al. The pharmacokinetics and bioavailability of cilazapril in normal man [J]. Br J Clin Pharmacol, 1989, 27 (Suppl. 2):181S-188S.
11. Nakamura M, Kawakita Y, Yasuhara A, et al. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo [3. 1. 0 ] hexane-2, 6-dicarboxylic acid), a potent metabotropic glutamate receptor antagonist [J]. Drug Metab Dispos, 2006, 34:369-374.
12. Borchardt RT. Optimizing oral absorption of peptides using prodrug strategies [J]. J Control Release, 1999, 62: 231-238.
13. Pauletti GM, Gangwar S, Siahaan TJ. Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies [J]. Adv Drug Deliv Rev, 1997, 27:235-256.
14. Cao F, Guo JX, Ping QN, et al. Ester prodrug of scutellar in: synthesis, physicochemical property and degradation [J]. Acta Pharm Sin 2006, 41:595-602.
15. Tunek A, Levin E, Svensson LA. Hydrolysis of 3H bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro [J]. Biochem Pharmacol, 1988, 37:3867-3876.
16. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems [J]. Adv Drug Deliv Rev, 1999, 36:229-254.
17. Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs [J]. J Med Chem, 2004, 47:2393-2404.
18. Lambert DM. Rationale and applications of lipids as prodrug carriers [J]. Eur J Pharm Sci, 2000, 11 (Suppl 2):S15-27.
19. Van den Mooter G. Colon drug delivery [J]. Expert Opin Drug Deliv, 2006, 3:111-125.
20. Hwang JJ, Marshall JL. Capecitabine: fulfilling the promise of oral chemotherapy [J]. Expert Opin Pharmacother, 2002, 3:733-743.
21. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery [J]. AAPS Pharm Sci, 2000, 2:E6.
22. Giles F, Estey E, O' Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia [J]. Cancer, 2003, 98:2095-2104.
23. Ware JA. Membrane transporters in drug discovery and development: a new mechanistic ADME era [J]. Mol Pharm, 2006, 3:1-2.
24. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut [J]. Gut, 2003, 52:1788-1795.
25. Anand BS, Dey S, Mitra AK. Current prodrug strategies via membrane transporters/receptors [J]. Expert Opin Biol Ther, 2002, 2:607-620.
26. Steffansen B, Nielsen CU, Brodin B, et al. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption [J]. Eur J Pharm Sci, 2004, 21:3-16.
27. Jain R, Duvvuri S, Kansara V, et al. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats [J]. Int J Pharm, 2007, 336: 233-240.
28. Rubio-Aliaga I, Daniel H. Mammalian peptide transporters as targets for drug delivery [J]. Trends Pharmacol Sci, 2002, 23:434-440.
29. Ganapathy ME, Brandsch M, Prasad PD, et al. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2 [J]. J Biol Chem, 1995, 270:25672-25677.
30. Terada T, Sawada K, Irie M, et al. Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2 [J]. Pflugers Arch, 2000, 440:679-684.
31. Beauchamp LM, Drr GF, de Miranda P, et al. Amino acid ester prodrugs of acyclovir [J]. Antiviral Chem Chemother, 1992, 3:157-164.
32. Han H, de Vrueh RL, Rhie JK, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter [J]. Pharm Res, 1998, 15:1154-1159.
33. Sawada K, Terada T, Saito H, et al. Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2 [J]. J Pharmacol Exp Ther, 1999, 291:705-709.
34. Englund G, Rorsman F, Ronnblom A, et al. Regional levels of drug transporters along the human intestinal tract; co-expression of ABC and SLC transporters and comparison with Caco-2 cells [J]. Eur J Pharm Sci, 2006, 29:269-277.
35. Jain R, Duvvuri S, Kansara V, et al. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats [J]. Int J Pharm, 2007, 336:233-240.
36. Testa B. Prodrug research: futile or fertile? [J]. Biochem Pharmacol, 2004, 68:2097-2106.
37. Van Gelder J, Shafiee M, De Clercq E, et al. Species-dependent and site-specific intestinal metabolism of ester prodrugs [J]. Int J Pharm, 2000, 205:93-100.
38. Yoshigae Y, Imai T, Aso T, et al. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa [J]. Life Sci, 1998, 62:1231-1241.
39. Minagawa T, Kohno Y, Suwa T, et al. Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases [J]. Biochem Pharmacol, 1995, 49:1361-1365.
40. Liederer BM, Borchardt RT. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human [J]. J Pharm Sci, 2005, 94:2198-2206.
41. Katoh M, Suzuyama N, Takeuchi T, et al. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport [J]. J Pharm Sci, 2006, 95:2673-2683.
42. Suzuyama N, Katoh M, Takeuchi T, et al. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport [J]. J Pharm Sci, 2007, 96:1609-1618.